Institute of Biochemistry II, Goethe University Frankfurt - Medical Faculty, University Hospital, Frankfurt, Germany
Valentina Diehl
Institute of Biochemistry II, Goethe University Frankfurt - Medical Faculty, University Hospital, Frankfurt, Germany
Verena Bittl
Institute of Biochemistry II, Goethe University Frankfurt - Medical Faculty, University Hospital, Frankfurt, Germany; Buchmann Institute for Molecular Life Sciences, Goethe University, Frankfurt, Germany
Rahel de Bruyn
Institute of Biochemistry II, Goethe University Frankfurt - Medical Faculty, University Hospital, Frankfurt, Germany
Svenja Wiechmann
Institute of Biochemistry II, Goethe University Frankfurt - Medical Faculty, University Hospital, Frankfurt, Germany; Project Group Translational Medicine & Pharmacology TMP, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Frankfurt, Germany
Institute of Biochemistry II, Goethe University Frankfurt - Medical Faculty, University Hospital, Frankfurt, Germany; Buchmann Institute for Molecular Life Sciences, Goethe University, Frankfurt, Germany
Institute of Biochemistry II, Goethe University Frankfurt - Medical Faculty, University Hospital, Frankfurt, Germany; Buchmann Institute for Molecular Life Sciences, Goethe University, Frankfurt, Germany; Frankfurt Cancer Institute, Frankfurt am Main, Germany; Cardio-Pulmonary Institute, Frankfurt am Main, Germany
Andreas Ernst
Institute of Biochemistry II, Goethe University Frankfurt - Medical Faculty, University Hospital, Frankfurt, Germany; Project Group Translational Medicine & Pharmacology TMP, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Frankfurt, Germany
Institute of Biochemistry II, Goethe University Frankfurt - Medical Faculty, University Hospital, Frankfurt, Germany; Frankfurt Cancer Institute, Frankfurt am Main, Germany; Cardio-Pulmonary Institute, Frankfurt am Main, Germany
Current technologies used to generate CRISPR/Cas gene perturbation reagents are labor intense and require multiple ligation and cloning steps. Furthermore, increasing gRNA sequence diversity negatively affects gRNA distribution, leading to libraries of heterogeneous quality. Here, we present a rapid and cloning-free mutagenesis technology that can efficiently generate covalently-closed-circular-synthesized (3Cs) CRISPR/Cas gRNA reagents and that uncouples sequence diversity from sequence distribution. We demonstrate the fidelity and performance of 3Cs reagents by tailored targeting of all human deubiquitinating enzymes (DUBs) and identify their essentiality for cell fitness. To explore high-content screening, we aimed to generate the largest up-to-date gRNA library that can be used to interrogate the coding and noncoding human genome and simultaneously to identify genes, predicted promoter flanking regions, transcription factors and CTCF binding sites that are linked to doxorubicin resistance. Our 3Cs technology enables fast and robust generation of bias-free gene perturbation libraries with yet unmatched diversities and should be considered an alternative to established technologies.